PITTSBORO, N.C., Oct. 7, 2020 /PRNewswire/ — Propella Therapeutics Inc. (Propella), a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer. The patent covers new molecules that are designed to provide significant advantages over the current standard of care. The patent, titled Abiraterone Prodrugs, […]
Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.
The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.
News coverage of our CGS-200-5 Phase 2 results for OA pain of the knee. Read Article
View the results of our Phase 2 clinical study of CGS-200-5 presented at the 2019 ACR Annual Meeting View Abstract
Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting